Ask AI
CAR T Cell Data From Summer Conferences

CME

Congress to Clinic: Clinical Advances Journal Club on Emerging CAR T-Cell Therapy Data From Summer Conferences ASCO, EHA, and ICML

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 30, 2025

Expiration: March 29, 2026

Pretest

Progress
1 2
Course Completed
1.

What was the primary result of lisocabtagene maraleucel for MZL in the phase II TRANSCEND FL study?

2.

Which of the following patients may be a candidate for treatment with arlocabtagene autoleucel in the ongoing phase III QUINTESSENTIAL-2 trial?

3.

Patient Case: 62-Yr-Old Woman With R/R MM



  • A 62-yr-old woman with multiple myeloma was previously treated for newly diagnosed disease with quad-based therapy

    • Treatment included a CD38 mAb, a proteasome inhibitor, and an immunomodulatory agent



  • She is now experiencing relapse while on lenalidomide maintenance

Based on current indications, which CAR T-cell therapy is the most appropriate treatment option for this patient?